Shannon R. Morris

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook et al. · The Lancet Oncology · 2012 · 558 citations

Medicine, Pharmacokinetics, Pharmacology +11

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Tibor Csőszi, Marina Maglakelidze, Robert J. Hoyer et al. · Annals of Oncology · 2019 · 169 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.

Robin Kate Kelley, Ghassan K. Abou‐Alfa, Johanna C. Bendell et al. · Journal of Clinical Oncology · 2017 · 168 citations

Medicine, Oncology, Pharmacology +17

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Andrew Spencer, Sung‐Soo Yoon, Simon J. Harrison et al. · Blood · 2014 · 140 citations

Medicine, Pharmacokinetics, Pharmacology +11

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Lowell L. Hart, Renata Ferrarotto, Zoran Andrić et al. · Advances in Therapy · 2020 · 125 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15